METHOD: COLLOIDAL GOLD METHODOLOGY features: FOR THE QUANTITATIVE MEASUREMENT OF CYSTATIN C Cystatin C Reagent The Sekisui Cystatin C assay uses a colloidal gold methodology that is unique to the cystatin C marketplace and is intended for the measurement of cystatin C concentration in human serum, heparinized plasma, or EDTA plasma. Since the introduction of rapid molecular tests and the 2018 FDA Flu reclassification focusing on the improved performance of on market rapid immunoassays, clinicians are now more confident in test results and therefore better able to provide direct therapy.CLINICAL chemistry REAGENTS Cystatin C measurements are used as an aid in the diagnosis and treatment of renal disease.
Testing patients provides valuable information to the clinician that can enable them to rule out other illnesses, help determine treatment and reduces the risk of prescribing unnecessary antivirals or antibiotics. "Accurate diagnosis of influenza is critical to minimize transmission of infection and we are proud to be able to provide sensitive and specific tools to healthcare professionals." We remain committed to providing innovative, high quality testing options so they can make the right choice for their practices and patients," said Robert Schruender, president /CEO of Sekisui Diagnostics. We take great pride in listening to our customers and we understand they have different needs during flu season. The launch of the Acucy Influenza A&B Test makes us the first and only company to provide the three most commonly used flu testing methods in a CLIA Waived format. "This is a very exciting time for Sekisui Diagnostics. Sekisui Diagnostics now offers options to address the varying needs of the market to help improve patient outcomes, maximize clinical efficiencies, and reduce operational budgets. Sekisui Diagnostics Osom Ultra Flu A&B Test Product Highlights Simple 5. The addition of the Acucy Influenza A&B test expands Sekisui Diagnostics flu portfolio to include all three commonly used modalities in the CLIA Waived environment: OSOM Ultra Flu A&B Test (manual read lateral flow), Acucy Influenza A&B Test (point-of-care reader) and the Silaris Influenza A&B Test (molecular point-of-care). Sekisui Diagnostics 7628 Rapid Microbial Testing Swabs Product Highlights Soft. Utilizing the Acucy Reader in either the point-of-care or laboratory setting provides workflow flexibility with Read Now and Walk Away features. in vitro diagnostics lead exposure lead toxicity maternal safety personal care point of care testing pregnancy-related complications rapid influenza test strep throat supply Chain zoonotic disease Read More. The combination of the Influenza A&B Test and the Reader provides clinicians with standardized and definitive result interpretation. delivers differentiated products, instrument systems, and services that support patient care. Our product lines include clinical chemistry and coagulation systems and. SEKISUI Diagnostics Invests 14.4 Million in cGMP Biopharma CDMO Capacity BURLINGTON, Mass., J/PRNewswire/ - Sekisui announces the decision to invest 14.4 Million in its biopharma CDMO business aimed at cGMP microbial capacity expansion at the existing site in Maidstone, Kent to be completed by the second half of 2022. We develop, manufacture, and supply billions of tests each year to the global healthcare market.
Salaries posted anonymously by Sekisui Diagnostics employees.
#Sekisui diagnostics free
The Acucy Influenza A&B Test is intended for the rapid, qualitative detection of influenza A and B viral nucleoprotein antigens from both nasal and nasopharyngeal swabs. For over 35 years Sekisui Diagnostics has been committed to providing innovative medical diagnostics to physicians and laboratories. A free inside look at Sekisui Diagnostics salary trends based on 12 salaries wages for 11 jobs at Sekisui Diagnostics. Food and Drug Administration (FDA), as well as, CLIA Waiver (Clinical Laboratory Improvement Amendments) for use on the Acucy Reader. Sekisui Diagnostics’ Acucy Influenza A&B Test has received 510(k) clearance as a Class II assay from the U.S.
0 kommentar(er)
